BIOMANUFACTURING FEATURED ARTICLES
Drug-Device Combination Products: 4 Evolving Platforms For 2026
Biologic advantage won’t come from better biology alone, but from delivery technology and designing the full experience around patients, providers, and supply chains.
-
![Scientist using Mass Spectrometry-GettyImages-1494345445]( "Evaluating Mass Spectrometry Methods For Host Cell Protein Quantification")
Evaluating Mass Spectrometry Methods For Host Cell Protein QuantificationNew USP 1132.1 guidelines standardize mass spectrometry for host cell protein analysis. These methods provide the specific protein identification and quantification needed to reduce clinical risk.
-
![GettyImages-1499814881-pills-production-line]( "How Drugs Are Manufactured And Administered")
How Drugs Are Manufactured And AdministeredModern medicine includes far more than familiar over‑the‑counter products. Explore how drug composition, formulation, and administration work together to shape today’s therapies.
-
![GettyImages-2228786791 MSC, stem cells]( "Scaling MSC Therapies: Overcoming Cell Therapy Manufacturing Risks And Barriers")
Scaling MSC Therapies: Overcoming Cell Therapy Manufacturing Risks And BarriersAchieve scalable MSC manufacturing by implementing closed systems and modular scale-out strategies that minimize contamination risks and ensure consistent cellular stability and efficacy.
BIOMANUFACTURING WHITE PAPERS & CASE STUDIES
-
![drug-developers-GettyImages-1309776504]( "Beyond Particle Counting: Why Modern Biologics Need Particle Forensics")
Beyond Particle Counting: Why Modern Biologics Need Particle ForensicsHigh particle counts don’t always mean high risk. Identifying particle type and origin—not just quantity—avoids false alarms, protects timelines, and turns data into action.
-
![Scientists in lab-GettyImages-1441665026]( "Optimize Time, Space and Cost With Inline Buffer Formulation And System")
Optimize Time, Space and Cost With Inline Buffer Formulation And SystemDiscover how integrating inline buffer formulation with chromatography reduces buffer waste by 50% and delivers a 710% ROI, transforming downstream efficiency and sustainability.
-
![GettyImages-2194013542-scientists-smiling-in-lab-discussing]( "Flexibility In Drug Development: From Tactical Response To Strategic Imperative")
Flexibility In Drug Development: From Tactical Response To Strategic ImperativeBuild flexibility into your drug development strategy to navigate change effectively, maintain momentum, and drive successful outcomes across every stage of the lifecycle.
-
![GettyImages-2173467618-vials-conveyor-belt]( "Early-Phase Injectable Formulation Development")
Early-Phase Injectable Formulation DevelopmentDiscover how expert-driven strategies and data-centric tools can help you overcome formulation challenges and accelerate the development of stable, high-performance injectable therapeutics.
-
![primary-drying-time-GettyImages-1464359399]( "The Effect Of Conventional Cooling Versus Controlled Ice Nucleation On Primary Drying Time")
The Effect Of Conventional Cooling Versus Controlled Ice Nucleation On Primary Drying TimeSee how controlled ice nucleation shortens lyophilization cycles, supports higher drying temperatures, and reduces complexity for amorphous and mixed formulations without sacrificing quality.
-
![clinical-trial-supply-challenges-GettyImages-2161372208]( "Biopharma Supply, Reimagined: Regional, Resilient Manufacturing")
Biopharma Supply, Reimagined: Regional, Resilient ManufacturingPersistent disruption is redefining biopharma supply chains. Explore how regional manufacturing, integrated risk management, and closer collaboration help build resilience and improve agility.
BIOMANUFACTURING PRODUCTS
Ensure efficiency in your upstream and downstream biopharma workflows with Charter Medical’s biological fluid management solutions.
From early-stage research to commercial-scale production, Charter Medical delivers integrated solutions that streamline your biopharma workflows.
As advanced therapy manufacturing evolves, maintaining the integrity of biological materials during cryopreservation steps is ever more critical.
Optimize single-use solutions for cryopreservation by engaging in studies that focus on specific timepoints and conditions pertaining to therapy storage, containment/protection, and transportation.
Charter Medical’s DEHP-free CryoProtect™ Bio-Containers are designed for intermediate, final fill, storage, and transport in bioprocessing applications using compatible freezing cassettes.
RoSS.ULTF is an upright ultra-low temperature storage freezer for frozen drug substances in different sizes. The ultra cold storage freezer keeps the desired set point temperature down to -80°C.
BIOMANUFACTURING MEDIA
In this episode of “Better Biopharma,” host Tyler Menichiello speaks with Michael McCullar, Ph.D., CEO at RegCell, a cell-therapy company developing regulatory T cell (Treg) therapies for autoimmune diseases.
Explore strategies for scaling MSC manufacturing while mitigating biological and operational risks. Learn how closed-system platforms and optimized workflows accelerate the path to commercial cell therapy.
A connected development pathway supports smoother scale-up and greater consistency for LNP-based therapeutics. Explore how integrated expertise across key stages helps teams accelerate progress.